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 HDL levels are profoundly decreased in chronic liver failure.
 HDL-related biomarkers (HDL-C, apoA-I) are robust predictors of
disease progression and survival.
 The prognostic value of single HDL-related biomarkers is very
similar to that of the composite scores.
 HDL-related biomarkers correlated inversely with markers of
inflammation.
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People who suffer from cirrhosis
(scarring of the liver) have low levels
of cholesterol carried by high-density
lipoproteins (HDL-C). These alter-
ations are connected to inflammation,
which is a problem in severe liver
disease. Herein, we show that reduced
levels of HDL-C and apolipoprotein A-I
(apoA-I, the main protein carried by
HDL) are closely linked to the severity
of liver failure, its complications and
survival. Both HDL-C and apoA-I can
be easily measured in clinical labo-
ratories and are as good as currently
used prognostic scores calculated
from several laboratory values by
complex formulas.
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levels are reduced in patients with chronic liver disease and
inversely correlate with disease severity. During acute conditions
such as sepsis, HDL-C levels decrease rapidly and HDL particles un-
dergo profound changes in their composition and function. We
aimed to determine whether indices of HDL quantity and quality
associate with progression and survival in patients with advanced
liver disease.
Methods: HDL-related biomarkers were studied in 508 patients
with compensated or decompensated cirrhosis (including acute-
on-chronic liver failure [ACLF]) and 40 age- and gender-matched
controls. Specifically, we studied levels of HDL-C, its subclasses
HDL2-C and HDL3-C, and apolipoprotein A1 (apoA-I), as well as
HDL cholesterol efflux capacity as a metric of HDL functionality.
Results: Baseline levels of HDL-C and apoA-I were significantly
lower in patients with stable cirrhosis compared to controls and
were further decreased in patients with acute decompensation
(AD) and ACLF. In stable cirrhosis (n = 228), both HDL-C and
apoA-I predicted the development of liver-related complications
independently of model for end-stage liver disease (MELD)
score. In patients with AD, with or without ACLF (n = 280), bothwords: HDL; apoA-I; MELD score; ACLF; Inflammation.
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Journal of Hepatology 2mortality. On ROC analysis, both HDL-C and apoA-I had high
diagnostic accuracy for 90-day mortality in patients with AD
(AUROCs of 0.79 and 0.80, respectively, similar to that of MELD
0.81). On Kaplan-Meier analysis, HDL-C <17 mg/dl and apoA-I
<50 mg/dl indicated poor short-term survival. The prognostic
accuracy of HDL-C was validated in a large external validation
cohort of 985 patients with portal hypertension due to advanced
chronic liver disease (AUROCs HDL-C: 0.81 vs. MELD: 0.77).
Conclusion: HDL-related biomarkers are robust predictors of
disease progression and survival in chronic liver failure.
Lay summary: People who suffer from cirrhosis (scarring of the
liver) have low levels of cholesterol carried by high-density
lipoproteins (HDL-C). These alterations are connected to
inflammation, which is a problem in severe liver disease. Herein,
we show that reduced levels of HDL-C and apolipoprotein A-I
(apoA-I, the main protein carried by HDL) are closely linked to
the severity of liver failure, its complications and survival. Both
HDL-C and apoA-I can be easily measured in clinical laboratories
and are as good as currently used prognostic scores calculated
from several laboratory values by complex formulas.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Chronic liver disease is a growing public health problem across
Europe and the United States.1,2 Since the liver plays an essential
role in several phases of lipid synthesis, transport, and meta-
bolism, hypocholesterolemia often occurs in patients with
cirrhosis.3 Cirrhosis is associated with a decrease in serum levels
of high-density lipoprotein cholesterol (HDL-C), low-density020 vol. 73 j 113–120
Research Article Cirrhosis and Liver Failurelipoprotein4 and apolipoprotein (apo) A-I, the main protein
component of HDL particles.5 Lipoprotein levels further decrease
with increasing severity of liver disease.6,7 Moreover, low HDL-C
and apoA-I levels significantly associate with death or need for
liver transplantation in patients with non-cholestatic cirrhosis8
and associate with the severity of septic disease and an exag-
gerated systemic inflammatory response.9 This is consistent with
the ability of HDL to bind and neutralize bacterial lipopolysac-
charide (LPS) and to promote excretion of these products,10,11
raising the possibility that HDL particles play a critical role in
the pathophysiology of chronic liver failure. HDL consists of 2
large subclasses, namely large, buoyant HDL2 particles and small,
dense HDL3 particles. Recent studies provided evidence that the
anti-inflammatory properties of HDL3 are superior to those of
HDL2.12 HDL3 effectively mobilizes cholesterol from cholesterol-
rich microdomains, which serve as signal platforms for Toll-like
receptors and thus attenuate the inflammatory response.13 This
may increase susceptibility of patients with cirrhosis to bacterial
infections, which are the most common triggers of acute-on-
chronic liver failure (ACLF).14 We have recently shown that
cirrhosis alters HDL composition and function and that HDL
cholesterol efflux capacity (CEC) predicted 12-month mortality
in patients with cirrhosis.15 However, the measurement of CEC is
very demanding and currently unsuitable as a routine clinical
test. In the present study, we investigated the prognostic value of
several HDL-related biomarkers that can be easily integrated into
routine clinical testing, i.e. HDL-C, apoA-I, and the HDL subclasses
HDL2-C and HDL3-C in a large cohort of patients with compen-
sated and decompensated advanced chronic liver disease (ACLD),




The patient population of this explorative cross-sectional study
included 508 patients with cirrhosis from 2 different cohorts: (i)
228 consecutive patients with stable cirrhosis recruited between
2011 and 2016 at the Medical University of Graz (outpatient
clinic or gastrointestinal ward including stable patients under-
going evaluation for liver transplantation) and (ii) 280 patients
with decompensated cirrhosis with or without ACLF who were
investigated between February and September 2011 in the
multicenter CANONIC study in 12 European countries (for
further details, see Moreau et al.16). In both studies, the diagnosis
of cirrhosis was based on liver histology or a combination of
clinical, biochemical and imaging signs. Patients with prior solid
organ transplantation or the presence of hepatocellular carci-
noma were excluded. Due to the impact of cholestasis on lipid
profiles, patients with cholestatic liver diseases were excluded.17
Hospitalized patients with cirrhosis were examined for the
presence of acute decompensation (AD) or ACLF as defined by
Moreau et al.16 Besides baseline data (history, physical exami-
nation, and laboratory measurements), information on liver
transplantation and mortality at 90 days and 12 months
following enrollment were recorded. In addition, data regarding
the occurrence of complications of cirrhosis were obtained in
patients with stable cirrhosis at baseline. Complications of
cirrhosis were defined as follows: development of new-onset
ascites in a patient without ascites at baseline, development of
new-onset hepatic encephalopathy, development of sponta-
neous bacterial peritonitis, hepatorenal syndrome, new-onset114 Journal of Hepatology 2jaundice (clinically detectable or bilirubin >3 mg/dl), upper
gastrointestinal bleeding due to portal hypertension (variceal
bleeding or bleeding from portal hypertensive gastropathy),
occurrence of portal vein thrombosis, or death from liver disease.
Besides, occurrence of severe infection requiring antibiotic
therapy within 12 months was assessed in patients with stable
cirrhosis.
Furthermore, 40 age- and sex-matched healthy controls who
did not meet the following exclusion criteria were included: any
history of cardiovascular disease, pregnancy, obesity, dyslipide-
mia, liver disease, renal disease, diabetes or clinical signs of
inflammation. Control participants did not take lipid-lowering
medication or anti-inflammatory drugs. Blood was sampled at
baseline from patients and healthy controls.
In addition, HDL-C was investigated in an external validation
cohort composed of 985 consecutive patients who underwent
hepatic venous pressure gradient (HVPG) measurement between
2004 and 2018 at the Vienna Hepatic Hemodynamic Lab at the
Medical University of Vienna (“HVPG cohort”). Patients with a
normal HVPG (<−5 mm Hg), porto-sinusoidal vascular disease,
cholestatic liver disease, transjugular intrahepatic portosystemic
shunt, a history of liver transplantation, or missing information
on HDL-C were excluded.
All 3 studies had been approved by the local Institutional
Review Boards (IRBs) in accordance with the Declaration of
Helsinki. Written informed consent was obtained from each
patient unless the requirement had been waived by the local IRB.
Lipid and cytokine assays
Levels of total cholesterol were measured enzymatically (Diasys,
Holzheim, Germany). The levels of total HDL-C and HDL3-C were
determined using homogeneous assays from Denka Seiken Co.,
Ltd. (Tokyo, Japan).18 HDL2-C was estimated by subtracting
HDL3-C from total HDL-C. ApoA-I was determined by immuno-
turbidimetry as described.19 Analyses were performed on an
Olympus AU680 analyzer (Beckman Coulter, Brea, USA). Cyto-
kines (interleukin [IL]-6, IL-8, tumor necrosis factor-a [TNF-a])
were quantified using a multiplexed bead-based immunoassay.
Preparation of apoB-depleted serum
ApoB-depleted serum was prepared by addition of 40 ll of pol-
yethyleneglycol (20% in 200 mmol/L glycine buffer) to 100 ll of
serum.15 Serum was incubated at room temperature for 20 min
and the supernatant recovered after centrifugation (10,000 rpm,
20 min, 4C).
HDL cholesterol efflux capacity
CEC was assessed using an established assay.20,21 J774 macro-
phages, maintained in DMEM with 10% fetal bovine serum were
plated on 48-well plates (300,000 cells/well). Cells were labeled
for 24 h with 1 lCi/ml [3H]-cholesterol (Perkin Elmer, Boston,
MA, USA). [3H]-cholesterol-labeled J774 macrophages were
incubated in the presence of 0.3 mmol/L 8-(4-chlorophenylthio)-
cAMP to stimulate ATP-binding cassette transporter A1 (ABCA1)
expression. After labeling, cells were washed twice with serum-
free DMEM and subsequently equilibrated in serum-free DMEM
containing 0.2% BSA for 2 h. After 2 additional washing steps,
[3H]-cholesterol efflux was determined by incubating cells for 3
h with serum-free DMEM containing 2.8% apoB-depleted serum.
Cholesterol efflux was expressed as the radioactivity in the me-
dium relative to total radioactivity in medium and cells. A control020 vol. 73 j 113–120
serum was used on each plate to decrease inter-plate variability.
All steps were performed in the presence of 2 lg/ml of the acyl
coenzyme A cholesterol acyltransferase inhibitor Sandoz 58-035
(Sigma, Darmstadt, Germany).
Composite prognostic scores
The prognostic value of HDL-related biomarkers (as single
prognostic parameters) was compared with established com-
posite prognostic scores as appropriate: (i) with the model for
end-stage liver disease (MELD) score in all patient groups, (ii)
with the Chronic Liver Failure Consortium (CLIF-C) AD score22 in
patients with AD, and (iii) with CLIF-C ACLF score23 in patients
with ACLF.
Statistical analysis
Continuous variables are reported by median (Q1–Q3) whereas
categorical data are presented as frequencies and percentages.
Non-normally distributed variables were compared non-
parametrically with Kruskal-Wallis tests using Bonferroni
correction for multiple comparisons. Correlations were analyzed
by Pearson product-moment estimates. Statistical analyses were
performed using GraphPad Prism (Version 4.0, GraphPad Soft-
ware) or SPSS Statistics Version 26 (SPSS Inc., Chicago, IL, USA).
Univariate binary logistic regression analysis was used to eval-
uate prognostic variables for development of complications.
Odds ratios estimated from logistic regression are reported with
corresponding 95% CIs. Nagelkerke's Pseudo-R2 is given for each
model as a measure of goodness-of-fit. Variables identified as
potential covariates (p <0.10) from univariate analyses were then
tested in multivariable logistic regression models. Competing
risk analysis was performed to assess the prognostic value of
HDL-related biomarkers for 90-day and 12-month mortality.
Either HDL or apoA-I was added to MELD and analyzed by
multivariable competing risk analysis with death as the event
and liver transplantation as a competing risk, using SAS version
9.4. In addition, the performance of prognostic variables was
tested by ROC analysis. AUROCs were compared by the method
of DeLong et al.24 using MedCalc version 14.10.2 (MedCalcTable 1. Characteristics of study participants.
Controls Stable
N 40
Age [years] 57 (48–64) 58









WBC [109/L] 6.0 (5.1–6.7) 5.1
PLT [109/L] 249 (218–270) 111
Bilirubin [mg/dl] 0.5 (0.4–0.7) 1.4
Creatinine [mg/dl] 0.8 (0.7–0.9) 0.8
INR 1.01 (0.98–1.04) 1.28 (1
Sodium [mmol/L] 140 (139–141) 139 (
Albumin [g/dl] 4.4 (4.3–4.6) 4.0
90-day mortality
12-month mortality
ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF-C, Chronic Liver Fai
disease; PLT, platelet count; WBC, white blood cell count. Data are shown as median (Q
Journal of Hepatology 2Software, Ostend, Belgium). The effect of prognostic variables on
mortality was analyzed by the Kaplan-Meier method and
compared by log-rank test. The results of the study are reported
following the TRIPOD (transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis) state-
ment recommendations.25Results
Patient characteristics
In total, 508 patients were enrolled in 2 cohorts, 228 patients
with stable cirrhosis in the Austrian single-center and 280 pa-
tients with AD in the European multicenter cohort. Among pa-
tients with stable cirrhosis, 131 patients (57.5%) were classified as
Child-Pugh class A, 74 patients (32.5%) Child-Pugh class B and 23
patients (10%) class C. Among the 280 patients with AD, 107 were
diagnosed with ACLF. Further details on characteristics of pa-
tients (including mortality data) and of controls are given in
Table 1. Patients who were transplanted during follow-up were
censored for ROC analyses. Nine patients with stable cirrhosis
(4%) were taking lipid-lowering drugs while this informationwas
not available for patients with AD. Due to the small number of
cases in the stable cirrhosis cohort and presumably low lipid-
lowering medication in patients with AD, no further analyses
with respect to lipid-lowering medication were performed. Pa-
tient characteristics of the external validation cohort from
Vienna (HVPG cohort) are given in Table S1.HDL-related biomarkers correlate with liver disease severity
We assessed HDL-C and apoA-I in all 508 patients and 40 age-
and gender-matched controls. Furthermore, the major HDL
subclasses HDL2-C and HDL3-C as well as CEC were determined
in a subset of 333 patients (228 patients with stable cirrhosis and
105 patients with AD). Median levels of total cholesterol and
HDL-related biomarkers, including HDL-C, HDL3-C, apoA-I, and
CEC, were significantly lower in patients with cirrhosis compared
to healthy controls and gradually decreased with increasing
severity of disease (Table 2, Fig. 1).cirrhosis AD ACLF
228 173 107





6 (5–8) 9 (8–11) 11 (10–13)
2 (9–16) 16 (12–20) 27 (22–33)
n.a. 52 (46–57) n.a.
n.a. n.a. 49 (43–56)
(3.9–6.5) 5.7 (4.1–8.2) 8.4 (5.3–12.3)
(79–150) 97 (59–141) 67 (42–114)
(0.8–2.8) 2.8 (1.4–5.6) 7.4 (2.3–18.7)
(0.7–1.0) 0.9 (0.7–1.2) 1.9 (0.9–3.2)
.16–1.48) 1.46 (1.27–1.75) 1.88 (1.40–2.52)
136–141) 136 (133–139) 134 (128–137)
(3.3–4.4) 2.9 (2.6–3.2) 3.0 (2.3–3.4)
4% 15% 42%
7% 27% 56%
lure Consortium; INR, international normalized ratio; MELD, model for end-stage liver
1–Q3). n.a., not applicable.
020 vol. 73 j 113–120 115
Table 2. HDL-related biomarkers.
Controls Stable cirrhosis AD ACLF
N 40 228 173 107
Cholesterol [mg/dl] 231 (199–285) 149 (120–181) 95 (73–126) 71 (42–100)
HDL-C [mg/dl] 63 (52–83) 47 (36–60) 22 (11–30) 11 (5–20)
HDL2-C [mg/dl] 30 (23–48) 28 (19–38) 13 (7–20) 5 (0–10)
HDL3-C [mg/dl] 32 (27–41) 18 (13–23) 11 (7–15) 6 (4–10)
ApoA-I [mg/dl] 178 (152–210) 122 (90–149) 69 (43–89) 33 (18–67)
CEC 12.2 (10.6–14.3) 9.7 (7.3–11.9) 5.8 (4.4–7.6) 4.6 (3.8–7.2)
AD, acute decompensation; ACLF, acute-on-chronic liver failure; apoA-I, apolipoprotein A1; CEC, cholesterol efflux capacity; HDL-C, high-density lipoprotein cholesterol. Data
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Fig. 1. HDL-related biomarkers are associated with severity of chronic liver
failure. Plasma samples of healthy controls (n = 40) and patients with SC
(n = 228), AD (n = 173) and ACLF (n = 107) were examined for levels of (A) HDL-
C and (B) apoA-I. *p <0.05, **p <0.01, ***p <0.001 vs. control; ###p <0.001 vs. SC;
§p <0.05, §§§p <0.001 vs. AD (Kruskal-Wallis test with Bonferroni correction).
ACLF, acute-on-chronic liver failure; AD, acute decompensation; ApoA-I,
apolipoprotein A1; HDL-C, high-density lipoprotein cholesterol; SC, stable
cirrhosis.
Table 3. Independent predictive factors with respect to development of
complications in stable cirrhosis (n = 228).
HR 95% CI p value R2
Univariate
HDL-C 0.96 0.94–0.98 <0.001 0.163
ApoA-I 0.97 0.96–0.98 <0.001 0.315
MELD 1.30 1.19–1.41 <0.001 0.334
Add to MELD
HDL-C 0.98 0.96–1.00 0.061
MELD 1.26 1.15–1.37 <0.001
Combined 0.346
ApoA-I 0.98 0.97–0.99 0.001
MELD 1.19 1.08–1.31 <0.001
Combined 0.387
Multivariable logistic regression. ApoA-I, apolipoprotein A1; HDL-C, high-density li-
poprotein cholesterol; HR, hazard ratio; MELD, model for end-stage liver disease; R2,
Nagelkerke’s R2.
Research Article Cirrhosis and Liver FailureHDL-related biomarkers correlate with inflammatory
markers
The pathophysiology of chronic liver failure is determined by
several factors, including systemic inflammation.26,27 Therefore,
we determined the concentrations of various inflammatory
markers in subsets of our cohort of patients with cirrhosis.
Compared to patients without ACLF, patients with ACLF showed
significantly higher numbers of white blood cells (Fig. S1A) and
higher C-reactive protein (CRP) levels (Fig. S1B), IL-6 (Fig. S1C)
and TNF-a (Fig. S1E), while IL-8 remained unchanged (Fig. S1D).
Levels of CRP increased progressively with stage of cirrhosis
(Fig. S1B). Since HDL shows anti-inflammatory activity, we next
investigated whether HDL-related biomarkers are associated
with indices or mediators of inflammation in these subsets.116 Journal of Hepatology 2Interestingly, we found strong negative associations of total
cholesterol and all HDL-related biomarkers (HDL-C, HDL2-C,
HDL3-C, apoA-I, and CEC) with white blood cell count, CRP, IL-6,
IL-8, and TNF-a (Table S2).HDL-related biomarkers predict complications and mortality
Complications of cirrhosis and mortality in patients with stable
cirrhosis
The predictive values of HDL-related biomarkers regarding
occurrence of complications within 12 months were assessed in
patients with stable cirrhosis at baseline (n = 228). 27 patients
had to be excluded due to insufficient follow-up (n = 8) or
insufficient data with respect to complications (n = 19). In total,
201 patients were included for analysis. Overall, complications
occurred in 77 of 201 patients (38%); usually more than 1
complication per patient was recorded (Table S3). In univariate
analysis, total cholesterol, HDL-C, HDL2-C, HDL3-C, apoA-I, CEC,
international normalized ratio, bilirubin, Child-Pugh and MELD
scores were associated with development of complications (data
not shown). In order to avoid multicollinearity, only 1 lipid-
related biomarker and MELD score were included in multivar-
iate analyses. Multivariable logistic regression yielded both
HDL-C and apoA-I as independent predictors of complications
(Table 3). On ROC analysis, HDL-C and apoA-I showed high
diagnostic accuracy for 12-month mortality (Fig. 2A) and for
development of complications within 12 months (Fig. 2B), with
AUROCs very similar to those of MELD. Interestingly, HDL-C and
apoA-I levels were significantly lower in patients who developed
severe infections requiring antibiotic therapy within 12 months
(HDL-C: 30 (20–48) mg/dl vs. 52 (42–65) mg/dl, p <0.001; apoA-















































































Fig. 2. HDL-related biomarkers predict complications and mortality. ROC curves illustrating the prognostic value of HDL-C, apoA-I and MELD score. (A) 12-
month mortality in stable cirrhosis; (B) development of complications within 12 months in stable cirrhosis; (C) 90-day mortality in AD/ACLF cohort; (D) 90-day
mortality in external validation set (HVPG cohort). ACLF, acute-on-chronic liver failure; AD, acute decompensation; ApoA-I, apolipoprotein A1; HDL-C, high-
density lipoprotein cholesterol; HVPG, hepatic venous pressure gradient; MELD, model for end-stage liver disease.
Table 4. Independent predictive factors of 90-day and 12-month mortality
in CANONIC patients (AD+ACLF, n = 280).
HR 95% CI p value
90-day mortality
Univariate
HDL-C 0.91 0.89–0.94 <0.001
ApoA-I 0.97 0.96–0.98 <0.001
Add to MELD
HDL-C 0.94 0.92–0.97 <0.001
MELD 1.09 1.05–1.13 <0.001
ApoA-I 0.98 0.97–0.99 <0.001
MELD 1.08 1.04–1.12 <0.001
12-month mortality
Univariate
HDL-C 0.94 0.93–0.96 <0.001
ApoA-I 0.98 0.97–0.99 <0.001
Add to MELD
HDL-C 0.97 0.95–0.99 0.004
MELD 1.07 1.04–1.11 <0.001
ApoA-I 0.99 0.98–0.99 0.019
MELD 1.07 1.04–1.11 <0.001
Competing risk analysis with death as event and liver transplantation as competing
risk. ACLF, acute-on-chronic liver failure; AD, acute decompensation; ApoA-I, apoli-
poprotein A1; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; MELD,
model for end-stage liver disease.Mortality in patients with AD
The impact of HDL-related biomarkers on mortality was assessed
in patients with AD with or without ACLF (n = 280) using
competing risk analysis. Both HDL-C and apoA-I showed high
predictive value for the outcomes of interest, i.e. 90-day and 12-
month mortality, on univariate analysis and remained indepen-
dent prognostic variables on multivariable analysis when added
to MELD (Table 4). On ROC analysis, HDL-related biomarkers
showed high diagnostic accuracy for 90-day mortality (Fig. 2C).
When our AD cohort was split into the first (n = 105) and second
(n = 175) dataset of CANONIC patients, ROC analysis yielded very
similar results (Fig. S2A-B). Furthermore, the prognostic value of
HDL-related biomarkers was compared with the CLIF-C AD score
for patients with AD and with the CLIF-C ACLF score for patients
with ACLF, again with similar results for HDL-related biomarkers
and the respective composite scores (Fig. S3A-B). Of note, in all
ROC analyses diagnostic accuracies of HDL-C and apoA-I were
very similar to that of MELD (Table 5). Calculation of YoudenJournal of Hepatology 2index identified optimal cut-offs of <17 mg/dl for HDL-C and of
<50 mg/dl for apoA-I for prediction of 90-day mortality. On
Kaplan-Meier analysis, baseline HDL-C or apoA-I values below
these cut-offs were associated with markedly lower 90-day
survival (Fig. 3A,B) and showed very similar prognostic value
as a baseline MELD of >−22 points (Fig. 3C).
Mortality in external validation cohort
In the external validation cohort from Vienna, including 985
patients with ACLD and portal hypertension (HVPG cohort), 54
patients died within 90 days. Again, HDL-C was an excellent
predictor of 90-day mortality (AUROC HDL-C: 0.81 vs. MELD:
0.77, p = 0.24 by DeLong test) (Table 5, Fig. 2D).
Discussion
In this explorative cross-sectional study, we show that HDL-
related biomarkers are robust predictors of disease progression
and survival, respectively, in the setting of stable cirrhosis and/or
AD. The prognostic values of HDL-C and apoA-I as single and
readily available parameters were very similar to those of the
composite scores MELD, CLIF-C AD and CLIF-C ACLF. Further-
more, the prognostic value of HDL-C was confirmed in a large
external validation cohort of patients with ACLD and portal
hypertension.
Several laboratory markers and functional scores have been
studied as predictors of mortality in patients with cirrhosis. The
Child-Pugh score comprises serum levels of bilirubin and albu-
min, prothrombin time, degree of ascites and severity of hepatic
encephalopathy and was originally introduced to predict mor-
tality in patients with cirrhosis undergoing surgery.28 The MELD
score was initially developed to predict mortality of patients
undergoing transjugular intrahepatic portosystemic shunt in-
sertions and employs serum levels of creatinine and bilirubin
and the international normalized ratio.29 We recently showed
that HDL maturation, metabolism and function is significantly
altered in patients with liver disease.15 The results of the present
study suggest that HDL-related biomarkers, such as HDL-C,
HDL3-C, apoA-I and CEC, reflect deterioration in liver function
and reliably predict disease progression, development of com-
plications and survival in patients with cirrhosis. HDL-C
and apoA-I can be easily measured in routine clinical labora-
tories and – as single parameters – show excellent diagnostic020 vol. 73 j 113–120 117
Table 5. Predictive discrimination of 90-day mortality by HDL-related biomarkers compared to composite prognostic scores.
AD/ACLF n = 280 AD n = 173 ACLF n = 107 HVPG cohort n = 985
AUROC (95% CI)
HDL-C 0.79 (0.73–0.85) 0.82 (0.74–0.89) 0.75 (0.64–0.85) 0.81 (0.76–0.87)
ApoA-I 0.80 (0.74–0.86) 0.82 (0.74 0.91) 0.73 (0.62–0.84)
MELD 0.81 (0.75–0.87) 0.81 (0.70–0.91) 0.72 (0.61–0.83) 0.77 (0.70–0.84)
CLIF-C AD score 0.72 (0.62–0.82)
CLIF-C ACLF score 0.75 (0.65–0.85)
ACLF, acute-on-chronic liver failure; AD, acute decompensation; ApoA-I, apolipoprotein A1; CLIF-C, Chronic Liver Failure Consortium; HDL-C, high-density lipoprotein


































































Fig. 3. Kaplan-Meier plots of survival probability in patients with acute decompensation of cirrhosis. (A) Mortality was significantly higher in patients with
HDL-C <17 mg/dl (p <0.001 by log-rank test). (B) Mortality was significantly higher in patients with apoA-I <50 mg/dl (p <0.001 by log-rank test). (C) Mortality was
significantly higher in patients with MELD >−22 (p <0.001 by log-rank test). ApoA-I, apolipoprotein A1; HDL-C, high-density lipoprotein cholesterol; HVPG, hepatic
venous pressure gradient; MELD, model for end-stage liver disease.
Research Article Cirrhosis and Liver Failureaccuracies for 90-day and 12-month mortality which are very
similar to those of composite scores such as Child-Pugh and
MELD. In particular, HDL-C and apoA-I decrease with increasing
severity of the disease regardless of the etiology of cirrhosis. Of
note, baseline HDL-C <17 mg/dl and apoA-I <50 mg/dl are asso-
ciated with dismal prognosis (90-day survival approx. 50%) and
those prove useful as single biomarkers of short-term survival.
Our findings are consistent with an earlier study by Poynard et al.
that investigated 581 patients with alcohol-related liver disease
and reported reduced 1-year survival of patients with cirrhosis
and apoA-I <100 mg/dl.7
Bacterial infections are common in cirrhosis and account for
significant mortality.30 They are facilitated by immune dysfunc-
tion that worsens with liver disease progression and frequently
results in ACLF.31,32 The risk of individuals with cirrhosis
becoming septic is more than doubled compared to the general
population and their clinical outcomes are dismal despite
intensive care.33–35 HDL regulates the cholesterol levels of cell
membranes through its ability to remove cholesterol and other
lipid species from cells, thereby reducing inflammatory receptor
signaling.13,36 HDL particles bind LPS and reduce cytokine pro-
duction and mortality in various animal models.37–39 Accord-
ingly, the susceptibility to LPS-induced liver damage is higher in
rats with cirrhosis than in healthy animals40 and decreases with
HDL administration.41,42
In a previous study, we observed that cirrhosis significantly
impaired the ability of HDL to suppress LPS-induced activation of
the proinflammatory transcription factor NF-jB in monocytes
and subsequent IL-6 and TNF-a production.15 In the present
study, we report a robust inverse association of HDL-related
biomarkers with white blood cell count, CRP, IL-6, IL-8, and
TNF-a. Furthermore, patients with subsequent infection showed
significantly lower levels of HDL-related biomarkers. In the
context of chronic liver failure, the immunomodulatory function118 Journal of Hepatology 2of HDL is of particular interest. Reduced HDL quantity and
function may play an important role in the pathophysiology of
systemic inflammation that drives the development of ACLF.27 In
line with this concept, an ex vivo study in patients with advanced
chronic liver failure has shown that the restoration of HDL
function by addition of reconstituted HDL reduces the LPS-
induced inflammatory response.43 It should be noted that a
similar therapeutic approach with reconstituted apoA-I (CSL112)
infusions has already been attempted in patients with myocar-
dial infarction and was found safe in a recent phase II study.44
This study has some limitations: our results, albeit robust, are
observational, do not prove causality and may be subject to
unmeasured confounders. Strengths of our study include the
large number of patients (n = 508) representing the whole
spectrum of chronic liver failure, separate analysis of individual
outcome parameters in patients with stable cirrhosis vs. AD,
long-term follow-up of the study cohort for at least 1 year, the
detailed assessment of multiple HDL-related biomarkers
focusing on readily available parameters (HDL-C, apoA-I), and
the confirmation of the prognostic value of HDL-C in a large
external validation cohort comprising 985 patients.
In conclusion, we report for the first time that HDL-related
biomarkers predict the development of complications in stable
cirrhosis, as well as predicting short-termmortality in the setting
of AD. The prognostic value of HDL-C and apoA-I as single bio-
markers was similar to currently used composite scores. Both
HDL-C and apoA-I provided incremental prognostic information
when added to MELD. Further research is needed to validate
HDL-related biomarkers as predictors of the development of
ACLF in cirrhosis.
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